Lupin’s partner ForDoz receives USFDA approval for doxorubicin hydrochloride liposome injection
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
The Product is expected to be the first generic approval on the market
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
Subscribe To Our Newsletter & Stay Updated